title: Cardiovascular risk in women with polycystic ovary syndrome.
abstract: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women that has received an immense amount of attention in the recent years due to the possible associated risk of cardiovascular disease. Women with PCOS demonstrate an adverse cardiovascular profile characteristic of the cardiometabolic syndrome and an established risk of progression to type 2 diabetes. Despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease, it is unclear if they develop accelerated atherosclerosis. This article summarized the recent development and findings of cardiovascular risk in women with PCOS, and finally the therapeutic options will be discussed.
authors: Department of Medicine, University of Hull, Hull, UK. l.cho@hull.ac.uk
authors: L W
authors: LW
authors: Cho
authors: S L
authors: SL
authors: Atkin
mesh_terms: D050197:Atherosclerosis / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D015444:Exercise; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D000077205:Pioglitazone; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012307:Risk Factors; D040242:Risk Reduction Behavior; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D015431:Weight Loss
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone; D008687:Metformin; D000077205:Pioglitazone